Sonoma Q1 revenue up; EBITDA turns positive as US demand surges
Sonoma Pharmaceuticals reported a Q1 inflection point with $6.4 million in revenue, a $2.4 million year-over-year increase. U.S. sales rose 141% to $1.4 million, while Europe grew 34% to $0.5 million, supporting margins of 40% and a positive EBITDA of $0.1 million. With $5.3 million in cash and ongoing FDA clearances and distribution partnerships, the company signals profitable growth potential ahead.
View signal analysis